ERAS
Price
$2.08
Change
+$0.27 (+14.92%)
Updated
Sep 26 closing price
Capitalization
590.03M
38 days until earnings call
ORIC
Price
$11.12
Change
+$0.71 (+6.82%)
Updated
Sep 26 closing price
Capitalization
1.08B
43 days until earnings call
Interact to see
Advertisement

ERAS vs ORIC

Header iconERAS vs ORIC Comparison
Open Charts ERAS vs ORICBanner chart's image
Erasca
Price$2.08
Change+$0.27 (+14.92%)
Volume$2.54M
Capitalization590.03M
Oric Pharmaceuticals
Price$11.12
Change+$0.71 (+6.82%)
Volume$1.19M
Capitalization1.08B
ERAS vs ORIC Comparison Chart in %
Loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORIC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERAS vs. ORIC commentary
Sep 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a StrongBuy and ORIC is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 29, 2025
Stock price -- (ERAS: $2.08 vs. ORIC: $11.12)
Brand notoriety: ERAS and ORIC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 260% vs. ORIC: 95%
Market capitalization -- ERAS: $590.03M vs. ORIC: $1.08B
ERAS [@Biotechnology] is valued at $590.03M. ORIC’s [@Biotechnology] market capitalization is $1.08B. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileORIC’s FA Score has 1 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • ORIC’s FA Score: 1 green, 4 red.
According to our system of comparison, both ERAS and ORIC are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 4 TA indicator(s) are bullish while ORIC’s TA Score has 5 bullish TA indicator(s).

  • ERAS’s TA Score: 4 bullish, 5 bearish.
  • ORIC’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ORIC is a better buy in the short-term than ERAS.

Price Growth

ERAS (@Biotechnology) experienced а +13.04% price change this week, while ORIC (@Biotechnology) price change was +5.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

Reported Earning Dates

ERAS is expected to report earnings on Nov 05, 2025.

ORIC is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ORIC($1.08B) has a higher market cap than ERAS($590M). ORIC YTD gains are higher at: 37.794 vs. ERAS (-17.131). ERAS has higher annual earnings (EBITDA): -135.93M vs. ORIC (-148.48M). ERAS has more cash in the bank: 301M vs. ORIC (283M). ORIC has less debt than ERAS: ORIC (3.27M) vs ERAS (49.4M). ERAS (0) and ORIC (0) have equivalent revenues.
ERASORICERAS / ORIC
Capitalization590M1.08B55%
EBITDA-135.93M-148.48M92%
Gain YTD-17.13137.794-45%
P/E RatioN/AN/A-
Revenue00-
Total Cash301M283M106%
Total Debt49.4M3.27M1,509%
TECHNICAL ANALYSIS
Technical Analysis
ERASORIC
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
84%
MACD
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 13 days ago
80%
Bullish Trend 24 days ago
85%
Declines
ODDS (%)
Bearish Trend 6 days ago
88%
Bearish Trend 4 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORIC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NRFNX11.520.12
+1.02%
Natixis AEW Global Focused Real Estate N
LGASX67.910.56
+0.83%
ClearBridge Small Cap FI
EIVDX16.240.13
+0.81%
Allspring Special Large Cap Value Admin
GGESX26.470.20
+0.76%
Nationwide Global Sust Eq Instl Svc
PJFAX67.130.27
+0.40%
PGIM Jennison Growth A

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+14.92%
XNCR - ERAS
56%
Loosely correlated
+12.00%
OCUL - ERAS
54%
Loosely correlated
+2.37%
RVMD - ERAS
50%
Loosely correlated
+3.32%
BEAM - ERAS
50%
Loosely correlated
-0.52%
CRNX - ERAS
50%
Loosely correlated
+27.92%
More

ORIC and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORIC has been loosely correlated with ERAS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ORIC jumps, then ERAS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORIC
1D Price
Change %
ORIC100%
+6.82%
ERAS - ORIC
48%
Loosely correlated
+14.92%
KYMR - ORIC
47%
Loosely correlated
+4.68%
NUVL - ORIC
47%
Loosely correlated
+4.99%
ROIV - ORIC
45%
Loosely correlated
+1.40%
IDYA - ORIC
44%
Loosely correlated
+4.44%
More